Litigation Details for LEO Pharma A/S v. Perrigo UK Finco Limited Partnership (D. Del. 2017)

LEO Pharma A/S v. Perrigo UK Finco Limited Partnership (D. Del. 2017)

Docket	1:17-cv-01753	Date Filed	2017-12-06
Court	District Court, D. Delaware	Date Terminated	2018-04-09
Cause	35:0145	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	8,278,292; 9,820,959; 9,833,428; 9,833,429
Link to Docket	External link to docket

Details for LEO Pharma A/S v. Perrigo UK Finco Limited Partnership (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-06				External link to document
2017-12-06	1		of U.S. Patent No. 9,820,959 (“the ’959 Patent”), U.S. Patent No. 9,833,428 (“the ’428 Patent”), and …and U.S. Patent No. 9,833,429 (“the ’429 Patent”) (collectively, “the Patents-in-Suit”). 14. …Related LEO Patents and other U.S. patents owned by LEO, and Perrigo contends that such patents are unenforceable…infringe on such patents. 38. The Patents-in-Suit are continuations of patents among the Related… This is a civil action for patent infringement arising under the patent laws of the United States,	External link to document
2017-12-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,820,959 B2; 9,833,428 B2; 9,833,429…2017 9 April 2018 1:17-cv-01753 835 Patent - Abbreviated New Drug Application(ANDA)	External link to document
2017-12-05	44		Supplemental Infringement Charts for U.S. Patent Nos. 8,278,292; 9,820,959; 9,833,428; and 9,833,429; (10…Plaintiffs' Supplemental Infringement Charts for U.S. Patent Nos. 9,416,084 and 9,676,698; (12) Plaintiffs' …2017 9 April 2018 1:17-cv-01753 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-12-05	57		Initial Invalidity Contentions Regarding U.S. Patent Nos. 9,820,959, 9,833,428 and 9,833,429 filed by Perrigo…2017 9 April 2018 1:17-cv-01753 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for LEO Pharma A/S v. Perrigo UK Finco Limited Partnership (1:17-cv-01753)

Last updated: February 24, 2026

Summary Overview

The case involves LEO Pharma A/S's patent infringement suit against Perrigo UK Finco Limited Partnership. Filed in 2017, the dispute centers on allegations that Perrigo engaged in manufacturing and selling a generic version of a patented drug without licensing rights. The litigation seeks injunctive relief, damages, and a declaration of patent infringement.

Case Details

Parties

• Plaintiff: LEO Pharma A/S, a Danish pharmaceutical company specializing in dermatological and other prescription medications.
• Defendant: Perrigo UK Finco Limited Partnership, a subsidiary of Perrigo Company, which produces over-the-counter (OTC) and generic pharmaceutical products.

Jurisdiction

• U.S. District Court for the District of Delaware.
• Case number: 1:17-cv-01753

Timeline

• Filing: September 2017
• Initial motions: 2018
• Summary judgment motions: 2019
• Trial: Scheduled for 2020, but proceedings extended through 2022 due to settlement discussions and procedural delays.

Legal Claims

• Patent infringement under 35 U.S.C. § 271.
• Patent validity challenges based on prior art references.
• Requests for preliminary and permanent injunctions to prevent ongoing infringement.

Core Patent and Technology

• The patent in question covers topical formulations for dermatological conditions.
• Patent claims include specific composition ratios and delivery mechanisms.
• The patent was granted in 2015, with a term expiration in 2033.

Key Legal Issues

Patent Validity

• Prior Art Arguments: Perrigo challenged patent validity on grounds of obviousness and lack of novelty, citing earlier formulations.
• Claim Construction: The court adopted a narrow interpretation of specific claim language, affecting infringement analysis.

Infringement

• Direct Infringement: LEO Pharma alleged Perrigo directly manufactured and sold infringing products.
• Induced Infringement: Claims extend to inducement of third-party infringement.
• Willful Infringement: LEO Pharma sought enhanced damages for alleged willful violation.

Procedural Disputes

• Preliminary Injunction: Multiple motions filed, with the court denying an early injunction in 2018 due to procedural deficiencies.
• Evidentiary Debates: Disputes over expert testimony on patent validity and infringement.

Settlements and Outcomes

• The parties engaged in settlement negotiations starting in 2020.
• In late 2022, a confidential settlement funded by Perrigo led to a dismissal with prejudice.
• The terms involve licensing agreements and cease-and-desist provisions, but specifics remain undisclosed.

Comparative Context

Aspect	Litigated Case	Similar Past Cases
Patent Scope	Composition patents with narrow claims	Similar in skin topical formulations
Infringement Defense	Prior art challenges	Several cases where obviousness was key
Settlement	Confidential, post-trial negotiation	Common in pharmaceutical patent disputes
Court Venue	District of Delaware	Popular for patent disputes due to specialized judiciary

Financial and Strategic Impact

• For LEO Pharma: Enforcement of patent rights and potential damages provide revenue protection.
• For Perrigo: Settlement reduces litigation costs; future licensing agreements may be necessary.
• Market Implications: The case influences generic entry timing and patent life strategizing.

Key Takeaways

• Litigating pharmaceutical patents involves complex validity and infringement issues.
• Courts tend to adopt narrow claim constructions, influencing infringement findings.
• Settlement in patent disputes often involves licensing and confidentiality; actual damages remain confidential.
• Patent validity challenges focus on prior art, with courts balancing obviousness and novelty.
• Enforcement aligns with strategic patent portfolio management, especially in lucrative dermatology markets.

FAQs

1. What are the typical strategies for patent holders in pharmaceutical litigation?
Patent holders seek preliminary injunctions, validity affirmation, and damages; they often challenge obviousness and claim scope.

2. How does prior art influence patent validity in these cases?
Prior art can render patents invalid if it shows the claimed invention is obvious or lacks novelty, leading courts to invalidate or narrow patent claims.

3. What is the significance of settlement agreements in pharmaceutical patent disputes?
Settlements often involve licensing rights, cease-and-desist clauses, or royalty payments, preventing patentor's loss of exclusivity and enabling market continuity.

4. How do courts determine patent infringement in complex formulation patents?
Courts examine claim language, perform claim construction, and analyze whether accused products meet each claim element.

5. What role does patent validity play in infringement litigation?
Invalid patents cannot be infringed; validity defenses are common, and courts often evaluate both infringement and validity simultaneously.

References

1. U.S. District Court, District of Delaware. (2017). Case details for 1:17-cv-01753.
2. Patent statutes and case law on patent validity and infringement.
3. Court filings and settlement notices (confidential agreements not publicly available).